Coursera Flash Sale
40% Off Coursera Plus for 3 Months!
Grab it
Explore cutting-edge developments in bispecific antibodies and T-cell engagers through this comprehensive webinar presented by GenScript's Amanda Grimm, an experienced life sciences professional with expertise in antibody drug discovery and immunopathology research. Discover how rapid advancements in cancer immunotherapy have positioned bispecific antibodies (BsAbs) and T-cell engagers (TCEs) as transformative therapeutic strategies, while learning about the unique challenges these complex molecules present in development, from selecting optimal formats to ensuring stability, efficacy, and manufacturability. Examine GenScript's latest innovations for BsAb development, including novel formats and AI/ML-driven optimization techniques that are revolutionizing the field. Gain insights into comprehensive solutions spanning gene synthesis, antibody engineering, high-throughput screening, and developability assessment that can accelerate the discovery and optimization of next-generation therapies. Learn how an integrated approach to antibody development can overcome key obstacles, streamline workflows, and enhance the success rate of novel immunotherapies, with opportunities to engage directly with the expert through live Q&A sessions throughout this 53-minute educational session.
